search
Back to results

Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study

Primary Purpose

Oral Squamous Cell Carcinoma

Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Bmi-1 antibody
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Oral Squamous Cell Carcinoma

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. In vitro studies.
  2. Samples used are oral dysplasia and squamous cell carcinoma.
  3. Diagnostic accuracy of Bmi-1 marker on oral dysplasia and SCC.
  4. English language published articles only.

Exclusion Criteria:

  1. In vivo studies.
  2. Studies using any techniques other than immunohistochemistry or PCR.
  3. Samples using any carcinoma rather than squamous cell carcinoma.
  4. Samples using benign tumors.
  5. Samples using sarcomas.

Sites / Locations

  • Asmaa M. Abou Gabal

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Immunohistochemistry

Polymerase Chain Reaction PCR

Arm Description

In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used. The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units.

Calculation of Relative Quantification (RQ) (relative expression): After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows: Finally, RQ was calculated according to the following equation: ∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene ∆∆ Ct = ∆ Ct sample - Ct control gene RQ = 2-(∆∆Ct)

Outcomes

Primary Outcome Measures

oral squamous cell carcinoma
Different grades of oral squamous cell carcinoma

Secondary Outcome Measures

Full Information

First Posted
November 10, 2017
Last Updated
November 14, 2017
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT03345966
Brief Title
Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study
Official Title
Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2017 (Anticipated)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
November 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the current study is to assess the validation of Bmi-1 detection at both protein and molecular levels in oral epithelial dysplasia and oral squamous cell carcinoma as a biomarker for early cancer detection versus biopsy embedded in paraffin blocks.
Detailed Description
Head and neck squamous cell carcinoma (HNSCC) including oral squamous cell carcinoma (OSCC) has been reported as the sixth most common cause of cancer mortality in the world and the fifth most commonly occurring cancer. Thus a compelling need for investigation of the underlying molecular events associated with OSCC tumorigenesis has emerged for better understanding of such lesion. Moreover, identification of biomarkers for early detection and prediction of prognosis became of extreme importance, as it was reported that early diagnosis has been vital for effective treatment of OSCC and improved the survival rate of OSCC patients. OSCC may originate from malignant transformation of the normal oral mucosa, as well as from oral potentially malignant lesions (OPMLs) with different degrees of oral epithelial dysplasia (OED). The approach of a step-wise transition from OPMLs to OSCC was well-established, but it could be difficult to predict if and when an OPML would undergo full transformation and resulted in a tumor. Thus, using specific molecular biomarkers able to identify OED lesions with higher potential for malignant transformation would be very beneficial. Unfortunately, up to date there has been no tools available to monitor OED lesions or HNSCC patients for early stages of local recurrences or distant metastases . Among the recently introduced biomarkers, B-lymphoma Moloney murine leukemia virus insertion region-1 (BMI1), a member of the polycomb group (PcG) genes, was considered to be pivotal in regulating stemness-related genes involved in maintaining the self-renewal ability of stem cells by promoting chromatin modifications. BMI1 was also known to be deregulated in various human types of cancer. Previous studies have revealed the capability of BMI1 to be used as a prognostic marker in gastric, esophageal, nasopharyngeal cancer, prostate, breast, cervical and ovarian cancer, However, the role of BMI1 in maintaining self-renewal and tumorigenicity in HNSCC or HNSCC-derived cancer stem cells (CSCs) remained to be clarified.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oral Squamous Cell Carcinoma

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Bmi-1 antibody using immunohistochemistry and PCR
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Immunohistochemistry
Arm Type
Experimental
Arm Description
In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used. The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units.
Arm Title
Polymerase Chain Reaction PCR
Arm Type
Experimental
Arm Description
Calculation of Relative Quantification (RQ) (relative expression): After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows: Finally, RQ was calculated according to the following equation: ∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene ∆∆ Ct = ∆ Ct sample - Ct control gene RQ = 2-(∆∆Ct)
Intervention Type
Diagnostic Test
Intervention Name(s)
Bmi-1 antibody
Other Intervention Name(s)
Expression of Bmi-1 molecule at RNA level by PCR and protein level by immunohistochemistry in oral dysplasia and squamous cell carcinoma
Intervention Description
B-lymphoma Moloney murine leukemia virus insertion region-1
Primary Outcome Measure Information:
Title
oral squamous cell carcinoma
Description
Different grades of oral squamous cell carcinoma
Time Frame
10 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: In vitro studies. Samples used are oral dysplasia and squamous cell carcinoma. Diagnostic accuracy of Bmi-1 marker on oral dysplasia and SCC. English language published articles only. Exclusion Criteria: In vivo studies. Studies using any techniques other than immunohistochemistry or PCR. Samples using any carcinoma rather than squamous cell carcinoma. Samples using benign tumors. Samples using sarcomas.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Asmaa M. Abou Gabal, Master
Phone
01016654242
Email
asmaaabougabal@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Asmaa M. Abou Gabal, Master
Phone
01223460340
Email
ahdytayel82@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Iman A. Radi, Professor
Organizational Affiliation
Cairo University
Official's Role
Study Chair
Facility Information:
Facility Name
Asmaa M. Abou Gabal
City
Cairo
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24415717
Citation
Dalley AJ, Pitty LP, Major AG, Abdulmajeed AA, Farah CS. Expression of ABCG2 and Bmi-1 in oral potentially malignant lesions and oral squamous cell carcinoma. Cancer Med. 2014 Apr;3(2):273-83. doi: 10.1002/cam4.182. Epub 2014 Jan 11.
Results Reference
result

Learn more about this trial

Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study

We'll reach out to this number within 24 hrs